ALHC CEO John E. Kao sells 180,000 shares at $17.286 avg price

Alignment Healthcare (ALHC) CEO and director John E. Kao reported the sale of 180,000 shares of common stock on 10/10/2025 under a Rule 10b5-1 trading plan adopted on 03/12/2025.

Rhea-AI Filing Summary

Alignment Healthcare (ALHC) CEO and director John E. Kao reported the sale of 180,000 shares of common stock on 10/10/2025 under a Rule 10b5-1 trading plan adopted on 03/12/2025.

The weighted-average sale price was $17.286, with individual trades ranging from $16.97 to $17.60. Following the transaction, beneficial ownership included 2,706,726 shares held indirectly by the JEK Trust and 2,839,942 shares held directly. A prior transfer on 09/25/2025 moved 1,693,626 shares from direct ownership to the JEK Trust.

Insider Trade Summary

Net Seller: 180,000 shares

Net Sell 2 txns

Insider KAO JOHN E

Role Chief Executive Officer

Sold 180,000 shs ($3.11M)

Type	Security	Shares	Price	Value
Sale	Common Stock	180,000	$17.286	$3.11M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,706,726 shares (Indirect, See Footnote); Common Stock — 2,839,942 shares (Direct)

Footnotes (4)

1. F1. Date of Rule 10b5-1 plan adoption: 03/12/2025
2. F2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.97 to $17.60. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
3. F3. Balances in column 5 reflect the transfer on 09/25/2025 of 1,693,626 shares held directly by Mr. Kao to the JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.
4. F4. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ALHC's CEO report in this Form 4?

John E. Kao reported selling 180,000 shares of Alignment Healthcare common stock on 10/10/2025.

At what prices were ALHC shares sold by John E. Kao?

The weighted-average price was $17.286, with trades ranging from $16.97 to $17.60.

Was the ALHC insider sale under a Rule 10b5-1 plan?

Yes. The plan was adopted on 03/12/2025.

How many ALHC shares does John E. Kao beneficially own after the sale?

Beneficial ownership included 2,706,726 shares indirectly via the JEK Trust and 2,839,942 shares held directly.

What is the relationship of John E. Kao to ALHC?

He is a Director and an Officer, serving as Chief Executive Officer.

What entity holds part of the ALHC shares indirectly?

The JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/14/2025 - 04:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE CA 92868

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/10/2025		S(1)		180,000	D	$17.286(2)	2,706,726(3)	I	See Footnote(4)
Common Stock								2,839,942(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 03/12/2025

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.97 to $17.60. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Balances in column 5 reflect the transfer on 09/25/2025 of 1,693,626 shares held directly by Mr. Kao to the JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

4. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.